Compare DuPont de Nemours Inc (DD) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DuPont de Nemours Inc vs TransMedics Group Inc — how do they compare? DuPont de Nemours Inc trades at $144.26 (market cap $19.51B), while TransMedics Group Inc trades at $89.69 (market cap $3.10B). The key difference: DuPont de Nemours Inc is far larger — about 6.3× TransMedics Group Inc's market cap, and DuPont de Nemours Inc pays a 1.66% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| DD | TMDX | |
|---|---|---|
Market Cap | $19.51B | $3.10B |
Sector | Basic Materials | Technology |
52-Week High | $154.59 | $150.42 |
52-Week Low | $90.24 | $61.99 |
Enterprise Value | $20.90B | $3.49B |
Dividend Yield | 1.66% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DuPont de Nemours Inc
DuPont is a diversified global specialty chemicals company created in 2019 as a result of the DowDuPont merger and subsequent separations. Its portfolio includes specialty chemicals and downstream products that serve the electronics and communication, automotive, construction, safety and protection, and water management industries. DuPont benefits from the ability to produce patented specialty chemicals that command pricing power. Noteworthy products include Kevlar, Tyvek, and Nomex have evolved over time to enable a wide range of applications across multiple industries.
Read more on DD →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
